Boehringer Ingelheim GmbH, of Ingelheim, Germany, and Eli Lilly and Co., of Indianapolis, said the FDA accepted for filing the new drug application for the SGLT2 inhibitor empagliflozin plus immediate-release metformin hydrochloride fixed-dose combination.